News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Rigel Pharmaceuticals, Inc. (RIGL) Release: Announces Participation at Two Investor Conferences



5/31/2012 2:21:11 PM

SOUTH SAN FRANCISCO, Calif., May 31, 2012 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, chairman and chief executive officer, and Raul Rodriguez, president and chief operating officer of Rigel, will participate at two upcoming investor conferences. Details of the events are as follows:

(Logo: http://photos.prnewswire.com/prnh/20030226/RIGLLOGO)

Jefferies 2012 Global Healthcare Conference
Presentation Date: June 5, 2012
Time: 2:30 PM ET
Location: New York, NY
Presenter: James M. Gower

Wells Fargo Securities Research & Economics
2012 Healthcare Conference
Presentation Date: June 19, 2012
Time: 1:30 PM ET
Location: Boston, MA
Presenter: Raul Rodriguez

Both events will be webcast live and can we accessed at www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral SYK inhibitor that is in Phase 3 clinical trials for rheumatoid arthritis with our partner AstraZeneca; R343, an inhaled SYK inhibitor that has completed Phase 1 clinical trials for asthma; R333, a topical JAK/SYK inhibitor for discoid lupus; and R548, an oral JAK3 inhibitor for the treatment of transplant rejection and other immune disorders.

Contact: Ryan Maynard
Phone: 650.624.1284
Email: invrel@rigel.com

SOURCE Rigel Pharmaceuticals, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES